Reported Saturday, Sanofi's Phase 3 COAST And SHORE Data Show Amlitelimab Achieves Up To 48.1% EASI-75 Response With Consistent Safety Profile In 1,833 Atopic Dermatitis Patients

Sanofi's Phase 3 studies for amlitelimab in atopic dermatitis, presented at a recent AAD session, involved 1,833 patients and demonstrated up to a 48.1% EASI-75 response rate. The results from the COAST 1, COAST 2, and SHORE studies indicated progressively increasing efficacy without evidence of plateau at Week 24. The data also support the potential for a Q12W dosing regimen.